补肺活血中药方在间质性肺疾病合并肺部感染患者中治疗效果及对肺功能影响

Clinical effects of the Bufei Huoxue prescription on pulmonary function of patients with interstitial lung disease plus lung infection

目的:探讨补肺活血中药方在间质性肺疾病合并肺部感染患者中的治疗效果及对肺功能的影响。方法:选取2014年2月-2015年11月我院收治的间质性肺疾病合并肺部感染患者86例为研究对象,采用随机分组表将患者分为研究组和常规组,常规组采用常规西药治疗,研究组在常规组治疗基础上采用自拟补肺活血中药方治疗,比较两组患者治疗效果及治疗前后氧分压(Pa O2)、二氧化碳分压(Pa CO2)、一氧化碳弥散率(DLCO)、肺总量(TLC)及药物不良反应。结果:研究组患者治疗总有效率(97.67%)显著高于常规组(83.72%),差异有统计学意义(P<0.05)。治疗前两组患者Pa O2、Pa CO2、DLCO、TLC水平比较,差异无统计学意义(P>0.05);治疗后研究组患者Pa O2、DLCO、TLC水平均高于常规组,Pa CO2水平低于常规组,差异有统计学意义(P<0.05)。两组患者肝功能受损、肾功能受损、胃肠不适及皮疹药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论:补肺活血中药方在间质性肺疾病合并肺部感染患者的治疗中可显著改善患者肺功能,提高临床疗效,具有较高的治疗效果和用药安全性。

Objective: To investigate clinical effects of the Bufei Huoxue prescription on pulmonary function of patients with interstitial lung disease plus lung infection. Methods: 86 cases from February 2014 to November 2015 in our hospital were enrolled in and randomly divided into the study group and conventional group. The conventional group adopt the conventional approach; the study group received the Bufei Huoxue prescription more. Results: The total efficiency (97.67%) in the study group was significantly higher than 83.72% in the conventional group, with a statistically significant difference (P<0.05). Before treatment, PaO2, PaCO2,DLCO, TLC levels in groups were not statistically significant (P>0.05); after treatment, PaO2, DLCO, TLC levels in the study group were higher; and PaCO2 in the study group was lower, P<0.05. Impaired liver function, impaired renal function, gastrointestinal discomfort and adverse reactions between groups showed no significant difference. Conclusion: The Bufei Huoxue prescription can significantly improve lung function of patients with interstitial lung disease plus lung infection, with higher clinical efficacy and safety.